Some HIV-infected – and untreated children – who do not develop AIDS, control the virus in a different way from the few infected adults who remain disease-free. Dr Maximilian Muenchhoff, DZIF
Prof Marcus Altfeld and Dr Angelique Hölzemer from the Heinrich Pette Institute (HPI) have been honoured with the "Hector Award HIV 2017”. Both scientists also work at the DZIF research field HIV.
The European Medicines Agency (EMA) has granted “PRIME eligibility” to Myrcludex B, and will provide priority support for its further drug development. The hepatitis B and D virus entry inhibitor was
Dr Vytenis Andriukaitis, EU Commissioner for Health and Food Safety, visited the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) to inform himself about multidrug-resistant pathogens
Researchers at the ImmunoSensation cluster of excellence at the University of Bonn have managed to do what many scientists dream of: together with researchers from the USA, they have patented new
The DZIF Academy is pleased to open the call for application for the fourth DZIF Prize for Translational Infection Research. The German Center for Infection Research (DZIF) will award a prize of 5.000
In 2016, a clinical phase I trial on a potential vaccine against the dreaded Ebola virus was successfully completed. The tested vaccine “rVSV-ZEBOV” proved to be safe and effective. In a further trial
Researchers from the University of Tübingen and the DZIF show medicine is effective when the timing is right. Their new active substance – DSM 265 – demonstrated a good prophylactic effect for Malaria
During pregnancy, a mother’s immune system is suppressed to protect the fetus, which is perceived as a foreign body because it is genetically different. A partly DZIF funded study in mice found that
This year, the Memento Research Award for neglected diseases goes to Dr Carsten Köhler and Prof Peter Kremsner from the Institute of Tropical Diseases at the University Hospital Tübingen. With this
